Skip to main content

Advertisement

SpringerLink
Log in

ERCC1 expression in triple negative breast carcinoma: the paradox revisited

  • Letter to the editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32

    Article  PubMed  CAS  Google Scholar 

  2. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728

    Article  PubMed  Google Scholar 

  3. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434

    Article  PubMed  Google Scholar 

  4. Tischkowitz M, Brunét JS, Bégin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134–144

    Article  PubMed  Google Scholar 

  5. Cleator S, Heller W, Coorbes (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244

    Article  PubMed  Google Scholar 

  6. Carey La, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334

    Article  PubMed  Google Scholar 

  7. Tan DSP, Marchiò C, Jones RL et al (2007) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. doi:10.1007/s10549-007-9756-8

  8. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Article  PubMed  CAS  Google Scholar 

  9. Al-Haddad S, Zhang Z, Leygue E et al (1999) Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155:2057–2066

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathologic Anatomy and Histology, Division of Cancer Research, University of Perugia, Perugia, 06122, Italy

    Angelo Sidoni & Fabio Cartaginese

  2. Medical Oncology Division, Azienda Ospedaliera, Perugia, Italy

    Mariantonietta Colozza, Stefania Gori & Lucio Crinó

Authors
  1. Angelo Sidoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Cartaginese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariantonietta Colozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefania Gori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucio Crinó
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Sidoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sidoni, A., Cartaginese, F., Colozza, M. et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res Treat 111, 569–570 (2008). https://doi.org/10.1007/s10549-007-9804-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9804-4

Keywords

Search

Navigation